- Home
- VRSK vs ARGX Comparison
VRSK vs ARGX Comparison
Compare VRSK & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRSK
- ARGX
- Stock Information
- Founded
- VRSK 1971
- ARGX 2008
- Country
- VRSK United States
- ARGX Netherlands
- Employees
- VRSK N/A
- ARGX N/A
- Industry
- VRSK Business Services
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRSK Consumer Discretionary
- ARGX Health Care
- Exchange
- VRSK Nasdaq
- ARGX Nasdaq
- Market Cap
- VRSK 41.7B
- ARGX 40.4B
- IPO Year
- VRSK 2009
- ARGX 2017
- Fundamental
- Price
- VRSK $297.62
- ARGX $591.87
- Analyst Decision
- VRSK Hold
- ARGX Strong Buy
- Analyst Count
- VRSK 10
- ARGX 20
- Target Price
- VRSK $295.40
- ARGX $682.00
- AVG Volume (30 Days)
- VRSK 885.8K
- ARGX 314.1K
- Earning Date
- VRSK 04-30-2025
- ARGX 05-08-2025
- Dividend Yield
- VRSK 0.61%
- ARGX N/A
- EPS Growth
- VRSK 60.67
- ARGX N/A
- EPS
- VRSK 6.71
- ARGX 12.78
- Revenue
- VRSK $2,881,700,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- VRSK $8.69
- ARGX $57.86
- Revenue Next Year
- VRSK $7.25
- ARGX $31.90
- P/E Ratio
- VRSK $44.12
- ARGX $43.78
- Revenue Growth
- VRSK 7.47
- ARGX 77.22
- 52 Week Low
- VRSK $217.34
- ARGX $352.77
- 52 Week High
- VRSK $306.10
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- VRSK 58.14
- ARGX 42.34
- Support Level
- VRSK $283.99
- ARGX $582.07
- Resistance Level
- VRSK $299.73
- ARGX $598.06
- Average True Range (ATR)
- VRSK 4.29
- ARGX 13.05
- MACD
- VRSK 0.63
- ARGX -0.35
- Stochastic Oscillator
- VRSK 86.84
- ARGX 33.69
About VRSK Verisk Analytics Inc.
Verisk Analytics is the leading provider of statistical, actuarial, and underwriting data for the United States' property and casualty insurance industry. Verisk leverages a vast contributory database and proprietary data assets to develop analytical tools helping insurance providers to better assess and price risk, achieve operational efficiency and optimize claim settlement processes. While Verisk also offers tools to quantify costs after loss events occur and to detect fraudulent activity, it is expanding into adjacent markets of life insurance, marketing, and non-US operations.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.